Measles Resurgence and the Cost of Declining Vaccination Rates: A Narrative Review of Global Coverage Gaps, Outbreak Dynamics, and Evidence-Based Pathways to Re-Establish Elimination, 2024–2026

 Measles Resurgence and the Cost of Declining Vaccination Rates: A Narrative Review of Global Coverage Gaps, Outbreak Dynamics, and Evidence-Based Pathways to Re-Establish Elimination, 2024–2026

Authors: Dr. Shekhar, Team, Doctor's Forum For All 🏥⚖️

Co author - Dr. Ankit

Disclaimer

This article is strictly for educational purposes only. It does not constitute medical advice or a substitute for professional clinical judgment. Readers should consult qualified healthcare providers for specific vaccination recommendations. The authors and Doctor's Forum For All 🏥⚖️ disclaim any liability for actions taken based on this content. All data cited are from publicly available sources as of the date of publication. The views expressed are those of the authors alone.

Abstract

Background: Measles, once on the verge of global elimination, has resurged dramatically across multiple continents. Seven countries lost their WHO measles elimination status in 2025–2026 alone. This review examines the scale of the resurgence, the coverage gaps driving it, and the evidence-based interventions that are successfully reversing the trend.

Methods: We conducted a narrative synthesis of WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) 2025 data, WHO and CDC outbreak surveillance reports, published literature on measles transmission dynamics and vaccination coverage, and documented case studies of successful catch-up campaigns and trust-building interventions from 2024 to 2026.

Results: Global measles coverage stalled at 84% for MCV1 and 77% for MCV2 in 2025, far below the 95% threshold required for herd immunity. An estimated 7.3 million infants started but did not complete their measles vaccination series. Fifty-seven countries reported large or disruptive measles outbreaks in 2025. Seven countries across three continents lost elimination status. The United States reported over 1,700 cases across 30 states in 2026 following its highest annual total in over 30 years. However, evidence from successful campaigns demonstrates that resurgence is reversible. Kenya protected over 16 million children in a 10-day campaign. Ethiopia reached 99% of its target in drought-affected districts. India's Andhra Pradesh state used microplanning and targeted drives to reach vulnerable children and strengthen its immunization system. Community engagement and trust-building interventions consistently improved uptake.

Conclusion: Measles resurgence is a consequence of declining vaccination coverage, not a failure of the vaccine. The tools to reverse it exist. What is needed is sustained investment in routine immunization, targeted catch-up campaigns, community-embedded trust-building, and political commitment. Elimination is achievable again. The evidence from 2025–2026 proves it.

Keywords: measles resurgence, vaccination coverage, measles elimination, catch-up campaigns, vaccine confidence, public health, herd immunity

Introduction

Measles was supposed to be history. In the Americas, elimination was achieved in 2000. In the UK, elimination was verified in 2017. Globally, deaths fell 88% between 2000 and 2024. The measles vaccine is safe, effective, and inexpensive. Two doses provide lifelong protection. The disease should be controllable.

It isn't. Not anymore.

In 2025–2026, seven countries across three continents lost their WHO measles elimination status. The United Kingdom became endemic again in January 2026. So did Spain, Austria, Armenia, Azerbaijan, and Uzbekistan. Canada lost its status the previous year. The United States reported over 1,700 cases across more than 30 states in 2026, following its highest annual total in over 30 years in 2025. The US elimination status, achieved in 2000, is now under review.

This is not a warning. It is a reversion. And it is happening because vaccination coverage has declined.

The numbers tell a stark story. Global coverage with the first dose of measles-containing vaccine (MCV1) stood at 84% in 2025. Second-dose coverage (MCV2) was 77%. The threshold for preventing sustained transmission is 95%. The gap is not small. It is the difference between protection and outbreak.

Fifty-seven countries reported large or disruptive measles outbreaks in 2025. In conflict zones, cases increased by more than 25% last year alone, with over 14,360 confirmed cases across 15 countries facing conflict in 2026. The Global Virus Network described the resurgence as "a scale not seen in decades".

The causes are multiple. Post-pandemic disruptions to immunization programs. Misinformation and declining public trust. Access barriers in fragile and conflict-affected settings. Vaccine hesitancy driven by fear of side effects. Together, these factors have created immunity gaps that measles exploits with ruthless efficiency.

But here is what the headlines often miss. The resurgence is reversible. The tools to reverse it exist. And they are working in places where they are applied.

Kenya vaccinated over 16 million children against measles, rubella, and typhoid in a 10-day campaign across all 47 counties in July 2025. Ethiopia reached 99% of its target in 38 drought-affected districts, identifying and vaccinating 2,574 children who had never received any immunizations. India's Andhra Pradesh state implemented targeted vaccination drives that reached vulnerable children and strengthened the state's immunization system against future outbreaks. In Kolkata's brick-kiln communities, frontline workers went door-to-door, building trust and bringing children into the fold.

These are not exceptions. They are proof of concept.

This article examines the measles resurgence through four questions. First, what does the 2025 coverage data actually show? Second, what are the consequences of declining coverage? Third, which interventions have demonstrated effectiveness in reversing the trend? Fourth, what does the path forward look like?

The stakes are high. Measles is one of the most contagious diseases known. It requires approximately 95% population immunity to prevent sustained transmission. Every percentage point below that threshold allows transmission chains to continue. Children who are unvaccinated or under-vaccinated face the highest risk. In the UK outbreak, over a quarter of infected children needed hospital treatment. In Birmingham, 78% of confirmed cases came from the city's most deprived areas. The risk of contracting measles in Black children aged 12–18 during that outbreak was estimated at 28.5 times that of white children of the same age.

Measles is not just a disease. It is a marker of inequality.

This article is written for health professionals, public health practitioners, policymakers, and informed readers. It argues that the resurgence is a solvable problem. The evidence from 2025–2026 shows that when governments invest, when communities engage, and when health workers are supported, coverage rises and outbreaks recede.

The vaccine works. The system around it needs to work too.

Methods and Materials

Study Design: This article is a narrative synthesis of publicly available surveillance data, peer-reviewed literature, and documented programmatic case studies. It is not a systematic review.

Setting and Population: The scope is global, with emphasis on countries and regions experiencing measles resurgence in 2024–2026. Data sources reflect populations of infants, children, and communities at risk of measles transmission.

Data Sources: The primary data sources were the WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) for 2025, released July 2026; WHO measles and rubella surveillance reports; CDC measles outbreak data for 2025–2026; published analyses in PLOS Medicine, BMJ, and JAMA Network on measles resurgence and vaccination coverage; WHO regional office reports from the Americas, Europe, Africa, and South-East Asia; and documented case studies of catch-up campaigns and community engagement interventions from WHO, UNICEF, Gavi, and PAHO publications.

Variables and Measurements: Coverage outcomes were measured as percentage of surviving infants receiving MCV1 and MCV2. Outbreak severity was assessed through reported case counts, hospitalizations, and country elimination status determinations. Intervention effectiveness was assessed through reported coverage rates achieved in catch-up campaigns and documented changes in vaccination intention or uptake following community engagement interventions.

Statistical Analysis: No primary statistical analysis was conducted. Published figures are reported as cited.

Ethical Considerations: This article uses only publicly available, de-identified aggregate data and published literature. No primary data collection involving human subjects was conducted. Institutional review board approval was not required.

Results

Coverage Data: Global Immunization in 2025

Global DTP3 coverage reached 85% in 2025, with 110 million infants completing the three-dose series. DTP1 coverage was 90%, representing nearly 116 million infants. These figures reflect a modest recovery from pandemic-era declines. They remain one percentage point below 2019 levels and have hovered within the same narrow range since 2009.

Measles coverage tells a different story. MCV1 coverage stood at 84%. MCV2 coverage was 77%. Both figures fall far short of the 95% threshold required to prevent outbreaks. An estimated 7.3 million infants received their first DTP dose but dropped out before receiving their first measles dose. These are children who started vaccination but did not finish. They are not refusers. They are the missed.

An estimated 13.5 million children were zero-dose in 2025, meaning they received no vaccines at all in their first year. More than half of zero-dose children live in fragile, conflict-affected, or vulnerable settings. In these settings, immunization programs are strained by political upheaval, insecurity, and chronic underfunding.

Outbreak Dynamics and Elimination Loss

Fifty-seven countries reported large or disruptive measles outbreaks in 2025. The United States reported 2,242 confirmed measles cases in 2025, including 3 deaths. In 2026, the US already reported more than 1,700 cases across over 30 states by April.

In Europe, the United Kingdom lost its measles elimination status in January 2026. Six other European countries—Spain, Austria, Armenia, Azerbaijan, and Uzbekistan—also lost elimination status. Romania accounted for a substantial share of European cases. In England, only 83.7% of 5-year-olds received both MMR doses in 2025. In the London borough of Enfield, coverage was 63.4%.

In conflict zones, measles cases increased by more than 25% in 2025. More than 14,360 confirmed cases were reported across 15 countries facing conflict in 2026. The Global Virus Network warned that large outbreaks driven overwhelmingly by declining vaccination coverage are raising concerns that the US could lose its elimination status.

The Cost of Declining Coverage

Measles is not a benign childhood illness. It causes pneumonia, encephalitis, and death. It also causes immune amnesia, erasing the body's memory of other infections and leaving survivors vulnerable to diseases they had previously overcome.

The UK outbreak data illustrate the clinical burden. Between January 1 and February 16, 2026, England recorded 130 laboratory-confirmed measles cases. Over a quarter of infected children needed hospital treatment. In the Birmingham outbreak of 2023–2024, 406 confirmed cases were reported. Seventy-eight percent came from the city's most deprived areas. None came from the least deprived. The risk of contracting measles in Black children aged 12–18 was 28.5 times that of white children of the same age. Inequalities in childhood vaccination uptake widened across England between 2019 and 2023, with the number of children susceptible to measles by age 5 increasing 20-fold in the most deprived areas.

This is what declining coverage looks like on the ground. Not a statistic. A child in a hospital bed.

What Works: Evidence from Successful Interventions

The resurgence is not inevitable. Documented interventions from 2025–2026 show that coverage can be restored and outbreaks contained.

Kenya conducted a 10-day vaccination campaign from July 5–14, 2025, delivering measles, rubella, and typhoid vaccines to over 16 million children across all 47 counties. The campaign achieved significant coverage rates and demonstrated the feasibility of rapid, large-scale catch-up.

Ethiopia targeted 38 drought-affected districts in a campaign that reached 441,794 children out of a target of 444,557—a 99% coverage rate. The campaign identified and vaccinated 2,574 children who had never received any immunizations and 2,734 who were under-vaccinated.

India's Andhra Pradesh state implemented three intensive seven-day measles-rubella vaccination drives between May and July 2025. The drives targeted left-outs and dropouts, reaching over 22,000 children with the first dose and more than 18,700 with the second dose. Microplanning became more precise. Coordination more effective. Surveillance systems more responsive. The state's experience demonstrated that data-driven planning and community engagement can bring even the hardest-to-reach populations into the fold.

In Kolkata, India, frontline workers and partners went door-to-door in brick-kiln communities, addressing concerns and preparing families ahead of vaccination camps. The intervention combined data-driven planning with community engagement. It worked.

What Works: Building Trust

Vaccine hesitancy is a real barrier. A global study found that parental trust in childhood vaccines declined after COVID-19, contributing to increased measles outbreaks. Fear of side effects was identified as the main driver—a concern that existed before the pandemic but intensified since.

But hesitancy is addressable. Evidence shows that when caregivers understand, trust, and participate in vaccination efforts, uptake improves dramatically. Community engagement interventions that build trust improve vaccine uptake and decrease hesitancy. In Rohingya refugee camps in Cox's Bazar, vaccination programs that engaged community leaders and addressed long-standing mistrust saw improved acceptance. In Nigeria, religious and community leaders played a pivotal role in building confidence.

The 7C model of vaccine hesitancy—confidence, complacency, calculation, convenience, collective responsibility, compliance, and conspiracy—offers a framework for understanding and addressing barriers. Clinician-led communication, accessible and free vaccination services, targeted social media engagement, and transparent informational dashboards are all essential tools for achieving effective disease management.

The Path Forward: Evidence-Based Recommendations

The evidence points to a clear set of priorities.

First, routine immunization must be strengthened. Catch-up campaigns are necessary, but they are not sufficient. Sustained coverage requires functional primary care systems that reach every child, every year.

Second, dropout must be addressed. The 7.3 million infants who start but do not complete measles vaccination represent a failure of retention, not acceptance. Reminder systems, follow-up visits, and integrated service delivery can close this gap.

Third, community engagement must be prioritized. Trust is built through relationships, not campaigns. Frontline health workers, community leaders, and religious figures are the most credible messengers. Investing in them is investing in the infrastructure of trust.

Fourth, equity must be central. Measles follows patterns of deprivation and exclusion. Coverage gaps are widest in the most vulnerable communities. Targeted interventions that reach these communities are essential.

Fifth, political commitment must be sustained. Elimination is not a one-time achievement. It is a continuous obligation. Countries that have maintained elimination have done so through sustained investment, strong surveillance, and rapid outbreak response.

Discussion

Key Findings

Three findings stand out.

First, the resurgence is real and widespread. Seven countries lost elimination status in 2025–2026. Fifty-seven countries reported large outbreaks. The United States, the United Kingdom, and multiple European countries are experiencing transmission that was eliminated years ago. The cause is declining vaccination coverage, not vaccine failure.

Second, the consequences are borne disproportionately by vulnerable populations. Children in deprived areas, racial and ethnic minorities, and those living in conflict zones face the highest risk. Measles is a marker of inequality. Where coverage is lowest, outbreaks are most severe.

Third, the resurgence is reversible. The evidence from Kenya, Ethiopia, India, and community engagement interventions demonstrates that when governments invest and communities engage, coverage rises and outbreaks recede. The tools exist. They are being used successfully.

Comparison with Prior Literature

These findings align with and extend previous analyses. The PLOS Medicine review on re-emergence of vaccine-preventable diseases identified measles as posing the greatest threat of widespread re-emergence, citing global declines in vaccine coverage due to pandemic disruptions, access barriers, and hesitancy. The BMJ analysis on measles and inequality demonstrated that outbreaks disproportionately harm children and vulnerable communities, and that public health leadership rooted in equity and rights is needed to avoid future outbreaks.

The WUENIC 2025 data confirm that global coverage has not recovered to pre-pandemic levels. The 84% MCV1 coverage figure is a plateau, not a recovery. The 77% MCV2 figure is dangerously low. The 7.3 million dropout children are the reservoir from which outbreaks emerge.

Limitations

This synthesis has limitations. It is not a systematic review. The literature selection was purposive and may have omitted relevant studies. Coverage data are national estimates and may mask substantial subnational inequities. Case studies of successful interventions are subject to publication bias; unsuccessful campaigns are less likely to be documented. The relationship between trust and vaccination is bidirectional and difficult to disentangle. Finally, the measles resurgence is a rapidly evolving situation, and data from 2026 are provisional.

Public Health Implications

The implications for policy and practice are direct and urgent.

First, health leaders must prioritize routine immunization. Catch-up campaigns are necessary for outbreak response, but they are not a substitute for functional primary care. The goal is not to vaccinate children once. It is to vaccinate them on time, every time, for every vaccine in the schedule.

Second, dropout must be treated as a system failure, not a parent failure. The 7.3 million children who start but do not finish measles vaccination are missed opportunities. Reminder systems, follow-up mechanisms, and integrated service delivery can close this gap. The tools are known. They need to be implemented.

Third, trust-building must be resourced. Community health workers, religious leaders, and frontline vaccinators are the most effective messengers. Investing in their training, their salaries, and their support systems is investing in vaccine confidence. The evidence from Kolkata, Nigeria, and Cox's Bazar demonstrates that trust can be rebuilt.

Fourth, equity must guide resource allocation. Measles outbreaks cluster in deprived communities. Coverage gaps are widest where resources are thinnest. Targeted interventions that reach the most vulnerable are not optional. They are the core of the strategy.

Fifth, political commitment must be sustained across election cycles and  competing priorities. Elimination is fragile. It requires constant vigilance. The countries that have lost elimination status did so because coverage slipped. The countries that maintain it do so because they never stopped investing.

Conclusion

Measles was eliminated in the Americas in 2000. It was eliminated in the UK in 2017. It was on the verge of elimination in multiple other countries. Now it is back.

The resurgence is not a mystery. It is a consequence. When coverage declines, measles returns. It is one of the most contagious diseases known. It requires 95% immunity to stop transmission. At 84% MCV1 coverage and 77% MCV2 coverage, the world is not protected. Fifty-seven countries reported large outbreaks in 2025. Seven lost elimination status. The United States is at risk of losing its status for the first time since 2000.

But the resurgence is reversible. The evidence from 2025–2026 proves it. Kenya vaccinated over 16 million children in 10 days. Ethiopia reached 99% of its target in drought-affected districts. Andhra Pradesh used microplanning and targeted drives to reach vulnerable children and strengthen its immunization system. Community engagement interventions in Kolkata, Nigeria, and Cox's Bazar rebuilt trust and improved uptake.

The path forward is clear. Strengthen routine immunization. Address dropout. Engage communities. Prioritize equity. Sustain political commitment. The tools exist. The evidence exists. What is needed is the will to use them.

Measles is a vaccine-preventable disease. Every outbreak is a failure of delivery, not of science. The vaccine works. The system around it needs to work too.

Elimination is achievable again. The question is whether we choose to achieve it.

References

1. Re-emergence of vaccine-preventable diseases in the post-elimination era. PLOS Medicine. 2026. doi:10.1371/journal.pmed.1005175.

2. Global Virus Network. On measles resurgence. News release. April 21, 2026.

3. World Health Organization, United Nations Children's Fund. WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) 2025. Geneva: WHO; 2026.

4. Pan American Health Organization. WHO and UNICEF estimates show routine immunization has rebounded in the Americas, but declining measles coverage leaves communities vulnerable to outbreaks. July 15, 2026.

5. UNICEF, WHO. Global childhood immunization coverage inches forward despite conflict and hesitancy. Press release. July 14, 2026.

6. Ramalingam B. Measles: children and vulnerable communities face disproportionate harms. BMJ. 2026;392:s499. doi:10.1136/bmj.s499.

7. Government of India, Ministry of Health and Family Welfare. Union Health Minister launches National Zero Measles-Rubella Elimination Campaign. April 24, 2025.

8. World Health Organization. Measles–Rubella vaccination drives boost immunization coverage in Andhra Pradesh, India. April 21, 2026.

9. World Health Organization. 16 million children protected in Kenya's measles, rubella and typhoid vaccination campaign. June 8, 2026.

10. World Health Organization. Reducing measles outbreak risk in 38 drought-affected districts in Ethiopia. November 4, 2025.

11. World Health Organization. Boosting immunization among the brick-kiln communities of Kolkata. May 13, 2026.

12. Gavi, the Vaccine Alliance. Vaccines work. Trust makes them reach every child. January 27, 2026.

13. Gavi, the Vaccine Alliance. From 'No' to eight 'Yeses': how a community changed its mind about vaccines. October 13, 2025.

14. Measles containing vaccine hesitancy and readiness in the post-COVID-19 era: A 7C model commentary. Journal of Global Health Science. 2025;7(5):391-394.

15. EurekAlert. New study shows global decline in parental trust in childhood vaccines after COVID-19, contributing to increased measles outbreaks. October 28, 2025.